|
|
|
|
|
| Advances in the immunomodulatory effects of blood purification on sepsis
|
| Pan Peng-fei, Li Wen-zhe, Du Xin-xin, Yu Xiang-you
|
| Department of Critical Care Medicine, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
|
|
|
|
|
Abstract Sepsis is a clinical syndrome characterized by systemic uncontrolled inflammatory response caused by infection, and is the most common cause of death in critically ill patients. Blood purification therapy has immunomodulatory functions through the nonspecific elimination of endotoxin and (or) inflammatory mediators, and shows a good prospect of application in sepsis. However, most of the current blood purification techniques do not show the benefits of improving the survival rate of patients with sepsis. In this paper, the mechanism of immunomodulation of blood purification and the progress of different blood purification techniques in sepsis are briefly reviewed, and the direction of the future immunomodulation is pointed out.
|
|
Received: 21 October 2017
|
|
Corresponding Authors:
Yu Xiang-you, E-mail：yu2796@163.com
|
|
|
|
| ［1］Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)［J］. JAMA, 2016, 315(8): 801-810.
［2］Quenot JP, Binquet C, Kara F, et al. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study［J］. Crit Care, 2013, 17(2): R65.
［3］Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016［J］. Intensive Care Med, 2017, 43(3): 304-377.
［4］Girardot T, Venet F, Rimmelé T. Immunomodulation: the future for sepsis［M］// Annual Update in Intensive Care and Emergency Medicine 2016. Springer International Publishing, 2016.
［5］Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis［J］. Artif Organs, 2003, 27(9): 792-801.
［6］Honoré PM, Matson JR. Extracorporeal removal for sepsis: Acting at the tissue level--the beginning of a new era for this treatment modality in septic shock［J］. Crit Care Med, 2004， 32(3): 896-897.
［7］Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis［J］. Int J Artif Organs, 2005, 8(8): 777-786.
［8］Rimmelé T, Kellum JA. High-volume hemofiltration in the intensive care unit: a blood purification therapy［J］. Anesthesiology, 2012, 116(6): 1377-1387.
［9］Peng Z, Singbartl K, Simon P, et al. Blood purification in sepsis: a new paradigm［J］. Contrib Nephrol, 2010, 165: 322-328.
［10］Villa G, Neri M, Bellomo R, et al. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications［J］. Crit Care, 2016, 20(1): 283.
［11］Joannes-Boyau O, Honoré PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial［J］. Intensive Care Med, 2013, 39(9): 1535-1546.
［12］Borthwick EM, Hill CJ, Rabindranath KS, et al. High-volume haemofiltration for sepsis in adults［J］.Cochrane Database Syst Rev, 2017, 1: CD008075.
［13］Park JT, Lee H, Kee YK, et al. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial［J］. Am J Kidney Dis, 2016, 68(4): 599-608.
［14］Quenot JP, Binquet C, Vinsonneau C, et al. Very high volume hemofiltration with the Cascade system in septic shock patients［J］. Intensive Care Med, 2015, 41(12): 2111-2120.
［15］Rimmer E, Houston BL, Kumar A, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis［J］. Crit Care, 2014, 18(6): 699.
［16］Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective［J］. Crit Care, 2014, 18(3): 309.
［17］Esteban E, Ferrer R, Alsina L, et al. Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge［J］. Mediators Inflamm, 2013, 2013: 507539.
［18］Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial［J］. JAMA, 2009, 301(23): 2445-2452.
［19］Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial［J］. Intensive Care Med, 2015, 41(6):975-984.
［20］Klein DJ, Foster D, Schorr CA, et al. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial［J］. Trials, 2014, 15: 218.
［21］Chang T, Tu YK, Lee CT, et al. Effects of polymyxin b hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis［J］. Crit Care Med, 2017, 45(8): e858-e864.
［22］Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial［J］. BMJ Open, 2014, 4(1): e003536.
［23］Hirasawa H, Oda S, Nakamura M, et al. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis［J］. Blood Purif, 2012, 34(2): 164-170.
［24］Honore PM, Jacobs R, Joannes-Boyau O, et al. Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review［J］. ASAIO J, 2013, 59(2): 99-106.
［25］Buffington DA, Pino CJ, Chen L, et al. Bioartificial Renal Epithelial Cell System (BRECS): a compact, cryopreservable extracorporeal renal replacement device［J］. Cell Med, 2012, 4(1): 33-43.
［26］Westover AJ, Buffington DA, Johnston KA, et al. A bio-artificial renal epithelial cell system conveys survival advantage in a porcine model of septic shock［J］. J Tissue Eng Regen Med, 2017, 11(3): 649-657.
［27］Lgters TT, Altrichter J, Paunel-Grgülü A, et al. Extracorporeal immune therapy with immobilized agonistic anti-Fas antibodies leads to transient reduction of circulating neutrophil numbers and limits tissue damage after hemorrhagic shock/resuscitation in a porcine model［J］. J Inflamm, 2010, 7: 18.
［28］Altrichter J, Sauer M, Kaftan K, et al. Extracorporeal cell therapy of septic shock patients with donor granulocytes: a pilot study［J］. Crit Care, 2011, 15(2): R82.
［29］Kellum JA, Gómez H, Gómez A, et al. Acute Dialysis Quality Initiative (ADQI) XIV sepsis phenotypes and targets for blood purification in sepsis: the Bogotá Consensus［J］. Shock, 2016, 45(3): 242-248.
［30］Shum HP, Yan WW, Chan TM. Extracorporeal blood purification for sepsis［J］. Hong Kong Med J, 2016, 22(5): 478-485.
|
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
